Tumor growth showed no difference between Caski/Ctrl and Caski/B3 tumors over the course of the experiment (Supplemental Figure 4B); however, Caski/B3 tumors had a significant increase in infiltrating CD11b+ myeloid cells compared with Caski/Ctrl tumors at days 22 and 40 after injection (Supplemental Figure 4C). Here, ITGAM is linked to neoplasm.